A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Psoriasis Clinical Trial

Official title:

A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03556202
• Other study ID #: 16491
• Secondary ID: I6T-MC-AMAH2017-
• Status: Terminated
• Phase: Phase 3
• Start date: September 3, 2018
• Est. completion date: February 7, 2022

Study information

• Verified date: March 2023
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1936
• Est. completion date: February 7, 2022
• Est. primary completion date: February 7, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant must have completed the last visit of an eligible study period of originating study.
• Participant must be willing to follow the birth control measures during and after study treatment if woman of childbearing potential.

Exclusion Criteria:

• Participant must not have an unstable or uncontrolled illness, including but not limited to a cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disease or abnormal lab results, that the study investigator thinks makes it unsafe or inappropriate for the participant to participate in this study.
• Participant must not have stopped taking mirikizumab during a previous study or if the study investigator thinks restarting mirikizumab would create an unacceptable risk to the participant.

Related Conditions & MeSH terms

• Psoriasis

Intervention

Drug:
• Mirikizumab
Administered SC

Locations

Country	Name	City	State
Argentina	Buenos Aires Skin	Buenos Aires	Ciudad Autónoma De Buenos Aire
Argentina	Centro de Investigaciones Metabólicas (CINME)	Buenos Aires
Argentina	Clinica Adventista Belgrano	Caba	Ciudad Autónoma De Buenos Aire
Argentina	Dermatology	Caba	Buenos Aires
Argentina	Instituto de Neumonología Y Dermatología	Capital Federal	Buenos Aires
Argentina	Halitus Instituto Médico	Ciudad Autonoma de Buenos Aire
Argentina	Psoriahue	Ciudad Autonoma de Buenos Aire	Buenos Aires
Argentina	Parra Dermatología	Mendoza
Australia	Clinical Trials SA Pty Ltd	Adelaide	South Australia
Australia	Skin Health Institute Inc.	Carlton	Victoria
Australia	Fremantle Dermatology	Perth	Western Australia
Australia	Woden Dermatology	Phillip	Australian Capital Territory
Australia	Veracity Clinical Research Pty Ltd	Woolloongabba	Queensland
Canada	Kirk Barber Research	Calgary	Alberta
Canada	Alberta DermaSurgery Centre	Edmonton	Alberta
Canada	Eastern Canada Cutaneous Research Assoicates Ltd	Halifax	Nova Scotia
Canada	Guenther Research Inc.	London	Ontario
Canada	Lynderm Research Inc.	Markham	Ontario
Canada	Innovaderm Research Inc	Montreal	Quebec
Canada	SKiN Centre for Dermatology	Peterborough	Ontario
Canada	Dr. Chih-ho Hong Medical Inc.	Surrey	British Columbia
Canada	K. Papp Clinical Research	Waterloo	Ontario
Czechia	Fakultni Nemocnice U svate Anny	Brno	Jihomoravský Kraj
Czechia	Kožní ambulance Kutná Hora, s.r.o.	Kutna Hora	Stredoceský Kraj
Czechia	Nemocnice AGEL Novy Jicin a.s.	Novy Jicin	Moravskoslezsky Kraj
Czechia	Clintrial s.r.o.	Praha	Praha 10
Czechia	Fakultni nemocnice Kralovske Vinohrady	Praha 10	Hl. M. Praha
Czechia	Etická komise Krajské zdravotní, a.s. - Masarykovy nemocnice v Ústí nad Labem, o.z.	Usti nad Labem	Ustecký Kraj
France	CHU de Bordeaux Hop St ANDRE	Bordeaux	Gironde
France	CH du Mans - Pavillon Claude Monet	Le Mans Cedex 1
France	CHU Dupuytren 2	Limoges	Cedex
France	Cabinet Médical	Martigues
France	Hopital Saint Eloi	Montpellier
France	CHU de Nice Hopital de L'Archet	Nice cedex 3
France	CHU Charles Nicolle in Rouen	Rouen cedex
France	Hopital Larrey	Toulouse cedex 9
Germany	Fachklinik Bad Bentheim	Bad Bentheim	Niedersachsen
Germany	Charité Campus Virchow-Klinikum	Berlin
Germany	ISA GmbH	Berlin
Germany	Klin. Forschung Berlin-Mitte GmbH	Berlin
Germany	Rothhaar Studien	Berlin
Germany	Dermatologisches Zentrum Osnabrück Nord	Bramsche	Niedersachsen
Germany	Elbe Klinikum Buxtehude	Buxtehude	Niedersachsen
Germany	Rosenpark Research GmbH	Darmstadt	Hessen
Germany	Hautarztpraxis Dr. Gerlach	Dresden	Sachsen
Germany	Klinikum der Johann Wolfgang Goethe-Universität Frankfurt	Frankfurt am Main	Hessen
Germany	Clinical Research Hamburg GmbH	Hamburg
Germany	TFS Trial Form Support GmbH	Hamburg
Germany	Universitaetsklinikum Hamburg-Eppendorf	Hamburg
Germany	Universitätsklinikum Heidelberg	Heidelberg	Baden-Württemberg
Germany	Universitätsklinikum Schleswig-Holstein	Kiel	Schleswig-Holstein
Germany	Universitätsklinikum Schleswig-Holstein	Lübeck	Schleswig-Holstein
Germany	Dermatologische Gemeinschaftspraxis Mahlow	Mahlow	Brandenburg
Germany	Universitätsklinikum Münster	Münster	Nordrhein-Westfalen
Germany	Hautarztpraxis Dr. Leitz	Stuttgart	Baden-Württemberg
Germany	Universitätsklinikum Tübingen	Tübingen	Baden-Württemberg
Hungary	Ambrozia Kft.	Budapest
Hungary	Uno Medical Trials Kft.	Budapest
Hungary	Debreceni Egyetem Klinikai Kozpont Borgyogyaszati Klinika	Debrecen	Hajdu-Bihar
Hungary	Bacs-Kiskun Megyei Korhaz	Kecskemét	Bács-Kiskun
Hungary	Oroshaza Varosi Onkormanyzat Korhaza	Oroshaza	Bekes
Hungary	Allergo-Derm Bakos Kft	Szolnok	Jasz-Nagykun-Szolnok
Hungary	Medmare Bt	Veszprém	Veszprém City
Israel	Haemek Medical Center- Dermatology	Afula
Israel	Soroka Medical Center	Beer Sheva
Israel	Rambam Medical Center	Haifa
Israel	Rabin Medical Center	Petach Tikva
Israel	Sheba Medical Center	Ramat Gan
Israel	Tel Aviv Sourasky Medical Center	Tel Aviv
Italy	Presidio Ospedaliero Firenze Centro Piero Palagi	Firenze
Italy	Policlinico di Tor Vergata	Roma
Italy	Policlinico Gemelli - Università Cattolica del Sacro Cuore	Roma	Lazio
Italy	Istituto Clinico Humanitas	Rozzano	Milano
Japan	Asahikawa Medical College Hospital	Asahikawa	Hokkaido
Japan	The University of Tokyo Hospital	Bunkyo-ku	Tokyo
Japan	Gifu University Hospital	Gifu
Japan	Tokyo Medical University Hachioji Medical Center	Hachioji	Tokyo
Japan	Kansai Medical University Hospital	Hirakata	Osaka
Japan	Tokyo Medical University Ibaraki Medical Center	Inashiki	Ibaraki
Japan	Tokai University Hospital- Isehara Campus	Isehara	Kanagawa
Japan	Nihon University Itabashi Hospital	Itabashi-ku	Tokyo
Japan	Teikyo University Hospital	Itabashi-ku	Tokyo
Japan	Shimane University Hospital	Izumo	Shimane
Japan	Kanto Rosai Hospital	Kawasaki	Kanagawa
Japan	Yamanashi Prefectural Central Hospital	Kofu	Yamanashi
Japan	Kurume University Hospital	Kurume	Fukuoka
Japan	Kyoto Furitsu Medical University Hospital	Kyoto
Japan	Gunma University Hosptial	Maebashi	Gunma
Japan	Shinshu University Hospital	Matsumoto	Nagano
Japan	Nagasaki University Hospital	Nagasaki
Japan	Nagoya City University Hospital	Nagoya	Aichi
Japan	Ryukyu University Hospital	Nakagami-gun	Okinawa
Japan	Kume Clinic	Nishi-ku Sakai-shi	Osaka
Japan	Takagi Dermatology	Obihiro	Hokkaido
Japan	Nippon Life Hospital	Osaka
Japan	Osaka City University Hospital	Osaka
Japan	Shiga University of Medical Science Hosptial	Otsu	Shiga
Japan	Toho University School of Medicine, Sakura Hospital	Sakura	Chiba
Japan	Tohoku University Hospital	Sendai-shi	Miyagi
Japan	Showa University Hospital	Shinagawa	Tokyo
Japan	NTT Medical Center Tokyo	Shinagawa-KU	Tokyo
Japan	Seibo Hospital	Shinjuku-ku	Tokyo
Japan	Tokyo Medical University Hospital	Shinjuku-ku	Tokyo
Japan	Takaokashi Shirasaki Dermatology Clinic	Takaoka	Toyama
Japan	Tokushima University Hospital	Tokushima
Japan	St. Luke's International Hospital	Tokyo
Japan	Mie University Hospital	Tsu	Mie
Japan	Yamaguchi University Hospital	Ube	Yamaguchi
Japan	Juntendo Urayasu Hospital	Urayasu	Chiba
Japan	Wakayama Medical University Hospital	Wakayama
Japan	Yokohama City University Hospital	Yokohama	Kanagawa
Korea, Republic of	Bucheon St. Mary's Hospital	Bucheon,	Gyeonggi-do
Korea, Republic of	Pusan National University Hospital	Busan	Korea
Korea, Republic of	Chungnam National University Hospital	Daejeon	Korea
Korea, Republic of	Ilsan Paik Hospital	Goyang-si	Gyeonggi-do
Korea, Republic of	Chonnam National University Hospital	Gwangju	Korea
Korea, Republic of	Gachon University Gil Hospital	Incheon	Korea
Korea, Republic of	Seoul National University Bundang Hospital	Seongnam-si	Gyeonggi-do
Korea, Republic of	Chungang University Hospital	Seoul
Korea, Republic of	Hanyang University Medical Center	Seoul	Korea
Korea, Republic of	Konkuk University Medical Center	Seoul
Korea, Republic of	Korea University Guro Hospital	Seoul	Seoul-teukbyeolsi [Seoul]
Korea, Republic of	Kyung Hee University Hospital	Seoul	Korea
Korea, Republic of	Samsung Medical Center	Seoul	Seoul-teukbyeolsi [Seoul]
Korea, Republic of	Seoul St. Mary's Hospital	Seoul	Korea
Korea, Republic of	Severance Hospital, Yonsei University Health System	Seoul
Korea, Republic of	CHA Bundang Medical Center, CHA University	Sungnam-si	Gyeonggi-do
Korea, Republic of	Ajou University Hospital	Suwon	Gyeonggi-do
Korea, Republic of	Ulsan University Hospital	Ulsan	Ulsan-Kwangyokshi
Mexico	RM Pharma Specialists S.A. de C.V.	Distrito Federal
Mexico	Instituto de Investigaciones Aplicadas a la Neurociencia A.C	Durango
Mexico	Grupo Clinico CATEI Sociedad Civil	Guadalajara	Jalisco
Mexico	B&B Investigaciones Medicas, SC	Mazatlan	Sinaloa
Mexico	Köhler & Milstein Research	Mérida	Yucatan
Mexico	Centro Medico del Angel	Mexicali	Baja California
Mexico	Hospital de Jesus I.A.P.	Mexico City	Distrito Federal
Mexico	Clinica De Enfermedades Cronicas y Procedimientos Especiales	Morelia	Michoacan
Poland	NZOZ Specjalistyczna Przychodnia Dermatologiczna Specderm	Bialystok	Podlaskie
Poland	NZOZ ZDROWIE Osteo-Medic	Bialystok	Podlaskie
Poland	Centrum Badan Klinicznych PI-House sp. z o.o.	Gdansk	Pomorskie
Poland	Centrum Medyczne Angelius Provita	Katowice	Slaskie
Poland	Diamond Clinic	Krakow	Malopolskie
Poland	Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna	Lodz	Lódzkie
Poland	Dermed Centrum Medyczne Sp. z o.o.	Lodz	Lodzkie
Poland	DermoDent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski s.c.	Osielsko	Kujawsko-pomorskie
Poland	Ai Centrum Medyczne Sp. Z O.O. Sp.K.	Poznan	Wielkopolskie
Poland	Lubelskie Centrum Diagnostyczne	Swidnik	Lubelskie
Poland	LASER CLINIC Specjalistyczne Gabinety Lekarskie	Szczecin	Zachodniopomorskie
Poland	Centrum Medyczne AMED	Warsaw	Mazowieckie
Poland	Centrum Medyczne Evimed	Warsaw	Mazowieckie
Poland	Centralny Szpital Kliniczny MSW Klinika Dermatologii	Warszawa
Poland	dermMedica Sp. z o.o.	Wroclaw	Dolnoslaskie
Puerto Rico	Santa Cruz Behavioral PSC	Bayamón
Puerto Rico	Dr. Samuel Sanchez PSC	Caguas
Puerto Rico	Office of Dr. Alma M. Cruz	Carolina
Puerto Rico	Ponce School of Medicine CAIMED Center	Ponce
Puerto Rico	GCM Medical Group, PSC - Hato Rey Site	San Juan
Russian Federation	GBUZ Clinical dermatology and venereological dispensary	Krasnodar	Krasnodarskiy Kray
Russian Federation	State scientific centre for dermatovenerology and cosmetolog	Moscow
Russian Federation	GOU VPO 'Smolensk State Medical Academy of Ministry of Health and Social Development of Russian Federation'	Smolensk
Russian Federation	SPb SBHI Skin-venerologic dispensary #10	St. Petersburg
Russian Federation	Tver State Medical University	Tver
Spain	Hospital del Mar	Barcelona
Spain	Hospital Germans Trias i Pujol	Barcelona	Badalona
Spain	Hospital De Basurto	Bilbao	Vizcaya
Spain	Hospital Reina Sofia	Cordoba
Spain	Hospital Infanta Leonor	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Ramón y Cajal	Madrid
Spain	Hospital de Manises	Manises	Valencia
Spain	Centro de Especialidades Mollabao	Pontevedra
Spain	Hospital Universitario Virgen Macarena	Sevilla
Spain	Hospital Universitario La Fe de Valencia	Valencia
Spain	Hospital Marina Baixa	Villajoyosa	Alicante
Taiwan	National Taiwan University Hospital - Hsinchu branch	Hsinchu
Taiwan	Chang Gung Memorial Hospital - Kaohsiung Branch	Kaohsiung
Taiwan	Taipei Medical University Shuang Ho Hospital	New Taipei City
Taiwan	Chung Shan Medical University Hospital	Taichung City
Taiwan	National Cheng-Kung Uni. Hosp.	Tainan
Taiwan	National Taiwan University Hospital	Taipei City
Taiwan	Chang Gung Memorial Hospital - Linkou	Taoyuan Hsien
United Kingdom	Salford Royal NHS Foundation Trust	Salford	Greater Manchester
United States	ORA, Inc	Andover	Massachusetts
United States	DelRicht Research	Baton Rouge	Louisiana
United States	Zenith Research, Inc.	Beverly Hills	California
United States	Bexley Dermatology Research	Bexley	Ohio
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	PMG Research of Cary, LLC	Cary	North Carolina
United States	University of North Carolina Dermatology and Skin Cancer Cen	Chapel Hill	North Carolina
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	Florida Academic Centers Research and Education, LLC	Coral Gables	Florida
United States	Modern Research Associates	Dallas	Texas
United States	University Dermatology	Darien	Illinois
United States	Psoriasis Treatment Center of Central New Jersey	East Windsor	New Jersey
United States	California Dermatology & Clinical Research Institute	Encinitas	California
United States	The Pennsylvania Centre for Dermatology, LLC	Exton	Pennsylvania
United States	Wright State Univ School of Medicine	Fairborn	Ohio
United States	Univ of Connecticut	Farmington	Connecticut
United States	First OC Dermatology	Fountain Valley	California
United States	Dawes Fretzin Clinical Research Group, LLC	Indianapolis	Indiana
United States	Clinical Partners, LLC	Johnston	Rhode Island
United States	Keck School of Medicine University of Southern California	Los Angeles	California
United States	Forefront Research	Louisville	Kentucky
United States	Dermatologic Surgery Specialists, PC	Macon	Georgia
United States	Advanced Clinical Research LLC	Meridian	Idaho
United States	University of Utah	Murray	Utah
United States	Mount Sinai School of Medicine Dermatology Clinical Trials	New York	New York
United States	Dermatology Clinical Trials	Newport Beach	California
United States	Virginia Clinical Research, Inc.	Norfolk	Virginia
United States	Renstar Medical Research	Ocala	Florida
United States	Park Avenue Dermatology	Orange Park	Florida
United States	Austin Institute for Clinical Research	Pflugerville	Texas
United States	The Indiana Clinical Trials Center	Plainfield	Indiana
United States	Oregon Dermatology and Research Center	Portland	Oregon
United States	Oregon Health and Science University	Portland	Oregon
United States	Oregon Medical Research Center	Portland	Oregon
United States	Dermatology and Skin Cancer Specialists	Rockville	Maryland
United States	Lawrence J Green, M.D, LLC	Rockville	Maryland
United States	Arlington Dermatology	Rolling Meadows	Illinois
United States	Central Dermatology PC	Saint Louis	Missouri
United States	Texas Dermatology and Laser Specialists	San Antonio	Texas
United States	San Luis Dermatology & Laser Clinic	San Luis Obispo	California
United States	Clinical Science Institute	Santa Monica	California
United States	Meridian Clinical Research	Savannah	Georgia
United States	Dermatology Associates	Seattle	Washington
United States	The South Bend Clinic Center for Research	South Bend	Indiana
United States	MultiCare Good Samaritan Hospital	Tacoma	Washington
United States	ForCare Clinical Research	Tampa	Florida
United States	PMG Research of Wilmington	Wilmington	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Canada,  Czechia,  France,  Germany,  Hungary,  Israel,  Italy,  Japan,  Korea, Republic of,  Mexico,  Poland,  Puerto Rico,  Russian Federation,  Spain,  Taiwan,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With a Static Physician's Global Assessment Among Those Who Entered the Study With a sPGA of 0,1	The sPGA is the physician's determination of the participant's psoriasis (PsO) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 104 were considered non-responders for non-responder Imputation (NRI) analysis.	Week 104
Primary	Percentage of Participants Who Maintained a =90% Improvements in Psoriasis Area and Severity Index (PASI) 90 Among Those Who Entered the Study With a PASI 90	PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).	Week 104
Secondary	Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)	PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).	Week 104
Secondary	Percentage of Participants With a Psoriasis Symptoms Scale (PSS) Symptom Score of 0 (Free of Itch, Pain, Stinging, and Burning) in Those With a PSS Symptoms Score =1 at Baseline	PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. In addition, a symptoms score ranging from 0 (no symptoms) to 40 (worst imaginable symptoms), and a sign score of 0 (no signs) to 30 (worst imaginable signs) will be reported.	Week 104
Secondary	Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Total Score of (0,1) With at Least a 5-Point Improvement (Reduction) From Baseline in Participants With a Baseline DLQI Total Score =5	The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Totals range from 0 to 30 (less to more impairment). A DLQI total score of 0 to 1 is considered as having no effect on a patient's health-related quality of life (HRQoL), and a 5-point change from baseline is considered as the minimal clinically important difference (MCID) threshold.	Week 104
Secondary	Change in Palmoplantar Psoriasis Severity Index (PPASI) Total Score in Participants With Palmoplantar Involvement at Baseline	The PPASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline.	Baseline, Week 104
Secondary	Change in Psoriasis Scalp Severity Index (PSSI) Total Score in Participants With Scalp Involvement at Baseline	The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity).	Baseline, Week 104
Secondary	Change in Nail Psoriasis Severity Index (NAPSI) Total Score in Participants With Fingernail Involvement at Baseline	The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix PsO by area of involvement. The fingernail is divided into quadrants. Each fingernail is given a score for fingernail bed PsO 0 (none) to 4 (PsO in 4 quadrants of the fingernail) and fingernail matrix PsO 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix PsO in each quadrant. The sum of all fingernails equals the total NAPSI score range is from 0 (no effect) to 80 (more severe psoriasis).	Baseline, Week 104

External Links

•   A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)